Order:
  1.  10
    Fair, Just and Compassionate: A Pilot for Making Allocation Decisions for Patients Requesting Experimental Drugs Outside of Clinical Trials.Arthur L. Caplan, J. Russell Teagarden, Lisa Kearns, Alison S. Bateman-House, Edith Mitchell, Thalia Arawi, Ross Upshur, Ilina Singh, Joanna Rozynska, Valerie Cwik & Sharon L. Gardner - 2018 - Journal of Medical Ethics 44 (11):761-767.
    Patients have received experimental pharmaceuticals outside of clinical trials for decades. There are no industry-wide best practices, and many companies that have granted compassionate use, or ‘preapproval’, access to their investigational products have done so without fanfare and without divulging the process or grounds on which decisions were made. The number of compassionate use requests has increased over time. Driving the demand are new treatments for serious unmet medical needs; patient advocacy groups pressing for access to emerging treatments; internet platforms (...)
    Direct download (3 more)  
     
    Export citation  
     
    Bookmark   1 citation  
  2.  51
    Public Stem Cell Banks: Considerations of Justice in Stem Cell Research and Therapy.Ruth R. Faden, Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Xiao-Jiang Gao, Mark Greene, John A. Hansen, Patricia A. King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel, Davor Solter, Sonia M. Suter, Catherine M. Verfaillie, LeRoy B. Walters & John D. Gearhart - 2003 - Hastings Center Report 33 (6):13-27.
    If stem cell-based therapies are developed, we will likely confront a difficult problem of justice: for biological reasons alone, the new therapies might benefit only a limited range of patients. In fact, they might benefit primarily white Americans, thereby exacerbating long-standing differences in health and health care.
    Direct download (5 more)  
     
    Export citation  
     
    Bookmark   9 citations  
  3.  20
    Safety Issues In Cell-Based Intervention Trials.Liza Dawson, Alison S. Bateman-House, Dawn Mueller Agnew, Hilary Bok, Dan W. Brock, Aravinda Chakravarti, Mark Greene, Patricia King, Stephen J. O'Brien, David H. Sachs, Kathryn E. Schill, Andrew Siegel & Davor Solter - 2003 - Fertility and Sterility 80 (5):1077-1085.
    We report on the deliberations of an interdisciplinary group of experts in science, law, and philosophy who convened to discuss novel ethical and policy challenges in stem cell research. In this report we discuss the ethical and policy implications of safety concerns in the transition from basic laboratory research to clinical applications of cell-based therapies derived from stem cells. Although many features of this transition from lab to clinic are common to other therapies, three aspects of stem cell biology pose (...)
    Direct download  
    Translate
     
     
    Export citation  
     
    Bookmark   4 citations